{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-118575","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.698000+00:00","generated_at":"2026-06-21T19:27:29.446242+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Onconova reports Q3 net loss $5.4M; plans Phase 1/2a narazaciclib trial in endometrial cancer in 1Q23","bullets":["Net loss of $5.4M ($0.26/share) vs $3.5M ($0.22) in Q3 2021; R&D expenses rose to $3.6M from $1.8M.","Cash and equivalents $42.6M as of Sep 30, 2022, down from $55.1M at Dec 31, 2021; expects to fund operations into 2024.","Plans to initiate Phase 1/2a trial of narazaciclib + letrozole in recurrent LGEEC in 1Q23; preliminary data expected 4Q23.","Rigosertib/nivolumab trial in KRAS-mutated NSCLC showed one complete response and two partial responses in 14 evaluable patients.","Rigosertib investigator-sponsored trials continue; Phase 2 melanoma trial on track for initiation."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-118575","json":"https://secwatch.observer/filing/0001104659-22-118575.json","markdown":"https://secwatch.observer/filing/0001104659-22-118575.md","text":"https://secwatch.observer/filing/0001104659-22-118575.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465922118575/0001104659-22-118575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465922118575/tm2230479d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:27:29.446242+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"229ce48c0853003397885552e3e02cf45136aec2","claim":"Traws Pharma, Inc. reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"On November 14, 2022, Onconova Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465922118575/0001104659-22-118575-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}